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Case presentations
Patient 1. A 17-year-old boy presented to his pediatrician 7 years ago
complaining of bright red urine that turned brown over the 3 days prior
to initial evaluation. At that time, he expressed concern that his
recently initiated sexual activity was the cause of his problem. He
otherwise was asymptomatic; a review of systems was entirely unre-
markable. The family history was noncontributory; one grandparent,
both parents, two sisters, and a brother were alive and well without
known chronic disease. The three deceased grandparents all had died in
their late sixties or early seventies of breast, colon, or lung cancer. No
personal or family history of renal stones, urologic neoplasia, hema-
tuna, deafness, urinary tract infections, or renal failure was elicited.
Physical examination revealed a well-developed, well-nourished white
male in no distress and without any discernible abnormality. Urinalysis
revealed straw-colored urine with a specific gravity of 1.017, I + protein
by dipstick, 15 to 20 erythrocytes/high-power field, and no casts, Urine
culture was sterile. Because he had played a tough soccer game the
previous week, hematuria was ascribed to strenuous exercise. He was
reassured that occasional episodes of gross hematuria occur for many
reasons in otherwise normal individuals, particularly after strenuous
exercise. He was advised to return if he had red urine again.
During the ensuing 4 months, the patient had two additional episodes
of gross hematuria, one documented by his pediatrician. Because of the
patient's anxiety and the recurrent nature of the hematuria, he was
referred for urologic evaluation. Several urinalyses revealed only 30 to
Presentation of the Forum is made possible by grants from Pfizer,
Incorporated; Merck Sharp & Dohme International; Sandoz, Incorpo-
rated; and E. R. Squibb and Sons, Incorporated.
© 1990 by the International Society of Nephrology
50 erythrocytes/high-power field or red cells too numerous to count.
Cystoscopy, retrograde pyelography and cystography, and an intrave-
nous pyelogram were normal.
On the day following the onset of yet another episode of bloody urine
(now 22 months after the initial presentation), the patient was evaluated
by a pediatric nephrologist, who documented macrohematuria; the
patient's history and review of systems were remarkable only for the 4
episodes of gross hematuria. Close questioning revealed that in at least
two instances, including the then-current episode, sore throat and a
flu-like illness had accompanied the hematuria. Physical examination
was remarkable only for pharyngitis, conjunctival injection, rhinitis,
and an oral temperature of 38.7°C. Blood pressure was 142/90 mm Hg.
Serum creatinine was 1.8 mg/dl; BUN, 48 mg/dl; albumin, 3.8 g/dl;
glucose, 95 mg/dl; sodium, 142 mEq/liter; potassium, 3.7 mEq/liter;
chloride, 98 mEq/liter; and bicarbonate, 26 mEq/liter. Urinalysis re-
vealed a pH of 5.8, a specific gravity of 1.020, 2+ protein, 4+ blood,
and numerous red blood cell casts and granular casts among erythro-
cytes too numerous to count. Urine protein excretion was 1.4 g124 hr.
One month later, the urine was clear, serum creatinine was 0.9 mg/dl;
BUN, 12 mg/dl; and blood pressure, 118/75 mm Hg. Three more similar
episodes occurred over the next 4 months; two occurred at the same
time as an episode of pharyngitis and all were accompanied by mild
acute renal insufficiency and transient hypertension.
The patient underwent a renal biopsy one day after the ninth episode
of gross hematuria, 2 years after initial presentation. The biopsy
revealed moderate mesangial hyperplasia and matrix hypertrophy, with
segmental endocapillary proliferation in approximately 30% of glomer-
uli. No sclerotic glomeruli, crescents, synechiae, or foci of tuft necrosis
were evident. No tubulointerstitial changes or vascular abnormalities
were observed. Immunofluorescent examination revealed moderate to
bright (2+ to 3+) granular mesangial deposits of IgA, C3, kappa and
lambda light chains, and moderate (1+ to 2+) IgG in the same
distribution. No significant 1gM, fibrin, Clq, or C4 was evident.
Ultrastructurally, niesangial hyperplasia and matrix hypertrophy were
confirmed; numerous 500—1000 nm electron-dense deposits were found
in the mesangial matrix, and rare similar deposits were apparent in the
paramesangium. The capillary walls were normal, save for segmental
irregular podocyte expansion. No other glomerular or tubular abnor-
mality was observed ultrastructurally.
Seven and one-half years after initial presentation, this young man is
active and healthy, with normal blood pressure and renal function.
Episodes of gross hematuria occur 2 or 3 times annually, but renal
function and blood pressure between episodes remain normal.
Patient 2. A 28-year-old man presented to his family physician
because his prospective insurance company required evaluation of the
2+ proteinuria detected on his pre-insurance screening. He had been in
his usual state of apparent good health and said that he felt fine. He was
regularly physically active, and a review of systems was unremarkable.
The patient was a new father of a baby girl. Both maternal grandparents
and a maternal uncle had died of coronary artherosclerosis and myo-
cardial infarction, and the paternal grandfather was being treated for
prostate cancer. All other first- and second-degree relatives were
healthy. There was no history of diabetes or renal disease in the family.
Physical examination revealed a healthy white male with a blood
pressure of 154/95 mm Hg; no other abnormality was found. The fasting
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serum glucose was 88 mg/dl; BUN, 32 mg/dl; creatinine. 1.6 mgldl;
albumin, 3.8 g/dl; total protein, 7.5 g/dl; cholesterol, 325 mg/dl; and
triglycerides, 182 mg/dl. Urinalysis revealed straw-colored fluid, a
specific gravity of 1.012, a pH of 6.2, and 2+ to 3+ protein, but no
ketones, blood, or bilirubin. Microscopic examination of the sediment
revealed numerous granular casts but no red cell, white cell, or fatty
casts. Followup over 6 months disclosed persistence of proteinuria,
mild azotemia, and intermittent microscopic hematuria (15—50 red blood
cells/high-power field). Persistent mild hypertension, documented dur-
ing the first 2 months of followup, was treated effectively with hydro-
chiorothiazide and a diet without added salt. Urinary protein excretion
ranged from 1.2 to 2.5 g124 hr. Renal biopsy was performed.
Light microscopic evaluation of the biopsy specimen revealed gb-
meruli with equivocal to mild increases in mesangial cellularity, mod-
erate expansion of mesangial matrix, and widely patent gbomerular
capillaries. The specimen contained no evidence of endocapillary
proliferation, crescent formation, or tuft necrosis. Sclerosis, manifested
by collapse of glomerular capillaries, was present in parts or all of 16%
of the 164 glomeruli present in all levels of the histologic sections. The
tubular interstitium contained rare foci of lymphohistiocytic infiltrates,
which were associated with mild edema and degenerative changes in
adjacent epithelium. No tubular atrophy or fibrosis was evident. The
cortical arterioles manifested medial hypertrophy, hyperplasia, and
hyalinosis, and these changes and intimal fibroelastosis also were
evident in a lobular artery. Immunofluorescent microscopy revealed
bright (3+) IgA, and moderate (2+) IgG, 1gM, C3, and kappa and
lambda chains, all in a granular mesangial pattern with some extension
to capillaries. No C4, Clq, or fibrin deposition was noted. Ultrastruc-
turally, expansion of mesangial matrix was accompanied by numerous
electron-dense deposits from 300—800 nm in size, predominantly in the
mesangium, but sometimes present in the paramesangium and glomer-
ular capillary walls. In addition, there were rare foci of thickening of
capillaries to approximately 500—600 nm, with lamellation and rarefac-
tion of the lamina densa. Irregular segmental broadening of epithelial
podocytes was evident.
Over 5 years, this patient has remained hypertensive; while receiving
captopril, 25 mg twice daily, he maintains a blood pressure of 140/90
mm Hg. Proteinuria has remained in the 1.5 to 2.0 g/24 hr range, and
microhematuria persists. Five and one-half years after initial evalua-
tion, the serum creatinine has risen to 2.1 mg/dl.
Discussion
DR. STEVEN N. EMANCIPATOR (Pathologist, University Hos-
pitals of Cleveland, and Associate Professor of Pathology,
Case Western Reserve University School of Medicine, Cleve-
land, Ohio): Given the different pathologic and clinical features
of these two patients, it is perhaps surprising that they share the
same diagnosis: IgA nephropathy (IgAN). Diverse as these two
examples are, they do not represent the clinical extremes of
IgAN, namely, the acute nephritic syndrome with acute renal
failure, and the nephrotic syndrome. Nor are diffuse, prolifer-
ative, necrotizing nephritis or minimal change by light micros-
copy—the pathologic poles of IgAN—illustrated by these two
patients. In addition, whereas the second patient is likely to
develop end-stage renal disease, the first patient is likely to
maintain good renal function, at least for the next 20 years.
Nevertheless, both patients are typical examples of IgAN, a
syndrome defined by the predominant deposition of IgA within
the glomerulus.
The first phase of investigation of IgAN consisted of a
descriptive collation of clinical and/or pathologic features;
several excellent recent reviews, including a prior Nephrology
Forum, distill these original series, and reach similar conclu-
sions about the disorder's attributes [1—7]. Nearly all patients
with IgAN (95%) have hematuria sometime during the course of
the disease. Its severity ranges from episodic macrohematuria
(54% of patients), which often is superimposed on persistent
microhematuria, to intermittent microhematuria. Proteinuria,
the next most frequently observed sign (found in 85% of
patients) generally is mild; about 50% of patients excrete less
than I g of protein per day, but proteinuria in excess of 2 g/24 hr
occurs commonly, and fully developed nephrosis is encoun-
tered in 5% to 10% of patients. Hypertension, acute renal
failure, and chronic renal failure, observed to a variable degree
and in various combinations, complete the clinical elements. By
light microscopy, nearly two-thirds of patients have only
mesangial abnormalities, manifest as some combination of
cellular proliferation and matrix expansion. The severity and
proportion of these features vary, not only from patient to
patient, but from glomerulus to glomerulus within the same
patient. Focal and segmental endocapillary proliferation, as in
Patient 1, is associated with mesangial changes in another 20%
of the patients, and another 14% have normal or minimally
altered glomeruli. Diffuse endocapillary proliferation is present
in only 5% of patients. Glomerular sclerosis, tuft necrosis,
and/or synechiae accompany all patterns of glomerular injury,
but with variable frequency and extent. By definition, IgA is the
predominant immunoglobulin, but biopsy reveals deposits of
IgG and/or 1gM in most patients without systemic disease
(75%). Alternative pathway and terminal complement compo-
nents (C3, properdin, factor B, the CSb-9 membrane attack
complex, and S regulatory protein) are nearly always present,
but classical pathway components (Cl, C4)are infrequent(12%
of patients) [8—241. Fibrin is not often deposited, except in
crescents and foci of tuft necrosis. The immune deposits are
nearly always in the mesangium, but they extend to the glomer-
ular capillary wall in some cases (10%). Ultrastructurally evi-
dent electron-dense deposits in the capillary wall correlate with
detection of capillary deposits by immunohistology. Increased
mesangial matrix and hypercellularity seen by electron micros-
copy parallel the changes observed by light microscopy.
Changes in the structural appearance of the capillary basement
membrane itself are well documented but of unknown signifi-
cance [25—27].
The second phase of investigation of IgAN charted the
clinical course of large numbers of patients. Originally consid-
ered a benign disease with little or no potential for progression,
we now know that IgAN results in end-stage renal disease in
roughly one-third of patients. Again, the results of many large
series, in which patients were followed for 10, 15, and even 20
years, are distilled in the several reviews I cited earlier [1—7].
Over the first 5 years, end-stage renal disease requiring dialysis
or transplantation occurs in I .f% to 1.5% of patients each year,
and in 0.5% of patients in each subsequent year; an even higher
incidence of chronic renal insufficiency is observed.
A significant milestone in our understanding of the natural
history of IgAN was reached with the recognition that a subset
of patients was at "high risk" for progression to total renal
failure. The statistically significant features more frequent in the
patients who ultimately develop chronic renal failure are: older
age at onset, lack of macrohematuria, urinary protein excretion
in excess of 1.5 to 2.0 g/24 hr, persistent hypertension, persist-
ent azotemia, glomerulosclerosis, interstitial cortical fibrosis,
circumferential crescents in more than 10% of glomeruli, exten-
sion of immune deposits from mesangium to glomerular capil-
laries, simultaneous abundant IgG or 1gM deposits, and arteri-
olar hyalinosis. Particularly important is the absence of
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macrohematuria, the presence of heavy proteinuria, persistent
azotemia, and sclerosis of vessels and/or glomeruli in the
biopsy; in several long-term series, these features consistently
portend a poor outcome [6, 14, 28—34].
Syndromes that typically herald IgAN. The marked variety of
clinical and pathologic features, as well as of long-term out-
comes, evokes the question, how are individual patients with
different attributes biologically related? Indeed, because IgAN
as we currently diagnose it—that is, glomerulonephritis with
predominance of the A class among glomerular immunoglobulin
deposits in the absence of systemic disease—is so varied in
clinical and pathologic expression, we must seriously consider
whether IgA deposition is only an epiphenomenon. Beukhof
and colleagues first proposed that a diagnosis of IgAN collects,
under an inappropriate umbrella, otherwise unrelated diseases,
each much more cohesive in clinical and pathologic detail and
natural history [34]. 1 will discuss the issues of the propriety of
the umbrella (IgA deposition as an epiphenomenon) and the
relatedness of different manifestations of diseases later, but
suffice it to say here that several investigators have categorized
patients with IgAN into a few distinct groups, each quite
cohesive in clinical features and prognosis [30—33]. Among
these, two are most prevalent: those patients with episodic
macrohematuria, often associated with acute renal insuffi-
ciency, as exemplified by Patient I, and those with proteinuria
associated with intermittent or persistent microhematuria, rep-
resented here by Patient 2. Henoch-Schonlein purpura, ne-
phrotic syndrome, and chronic renal failure round out the
clinical spectrum of glomerular disease with predominantly IgA
deposits. The former two modes of presentation comprise
respectively some 55% and 35% of patients with IgAN, while
the latter three modes each represent roughly 3% to 5% of
adults. In children, Henoch-SchOnlein purpura accounts for
10% to 15% of patients with IgAN. The relationship of Henoch-
SchOnlein purpura to IgAN is well discussed elsewhere [35, 36]
and does not bear repetition here. By definition, IgAN can only
be diagnosed by renal biopsy. Hence, where asymptomatic
microhematuria, alone or in association with low-grade protein-
uria and normal renal function, is not an indication for biopsy,
patients with these low-grade signs of disease do not contribute
to the pooi of IgAN patients. In locales where renal biopsy is
performed in such individuals, approximately 60% of patients
with this mode of clinical expression have predominantly IgA
and C3 deposits, and therefore IgAN [37, 381, In most nations,
signs more overt than microhematuria are required for biopsy,
and patients therefore usually fall into two basic groups: those
with episodic macrohematuria and those with microhematuria
and proteinuria.
I believe that these two prominent modes of disease expres-
sion, that is, episodic macrohematuria and asymptomatic mi-
crohematuria with proteinuria, are indeed related pathogeneti-
cally, pathophysiologically, and immunologically, and that the
diagnostic term IgAN is not an inappropriate umbrella. Patients
who present with episodic macrohematuria tend to be younger,
with bouts of hematuria closely associated in time with phar-
yngitis, coryza, or other "flu-like illness." Although one-half of
all patients with IgAN give a history of viral illness associated
with disease onset, patients with episodic macrohematuria
comprise most of the patients with pharyngitis occurring con-
comitantly with nephritis. Conversely, few IgAN patients lack-
ing a history of a "viral syndrome" associated with nephritis
have macroscopic hematuria. Infectious episodes, then, seem
to precipitate episodic macrohematuria. A more subtle element,
as yet undefined, appears to underlie the microhematurial
proteinuria mode of disease expression.
I believe that in each of these modes of clinical presentation,
distinct defects in the regulation of immune responses, partic-
ularly of mucosa-associated lymphocytes, might well explain
the pathogenesis of IgAN. Indeed, aberrations in immune
function and lymphocyte markers have been recognized in
IgAN, although such studies have not categorized patients into
the aforementioned clinical subgroups. Review of these issues
of disordered immune regulation permits development of a new,
working hypothesis on IgA nephritogenesis. In this Forum, I
will define IgAN as an immune-complex glomerulonephritis
with IgA antibody specific for unknown foreign antigen(s); this
perspective is based on reasons presented elsewhere [5, 7].
Others have proposed that IgA with autoimmune specificity,
particulary IgA rheumatoid factor or IgA aggregated for non-
immune reasons, are sources of IgA deposits in glomeruli.
Some investigators have contended that the IgA in glomerular
deposits is in fact the antigen component of immune complexes
with anti-IgA antibodies. In all these alternate hypotheses, IgA
must be synthesized. However, in all cases, IgA synthesis is
likely subject to the same isotype-specific regulation as physi-
ologic IgA antibody synthesis. Hence, the influences on regu-
lation of IgA production I will discuss presently apply to
nephritogenesis under these alternate hypotheses as well, al-
though perhaps with modification.
Special features of regulation of mucosal immune responses.
IgA has a special relationship to mucosae and to mucosa-
associated lymphoid tissue [39, 40]. Some plasmacytes within
the bone marrow, and also in spleen and lymph nodes remote
from mucosae, contribute to the total-body IgA pool. But IgA
production by these latter tissues is far overshadowed by cells
derived from mucosa-associated B cells. These B-cell-derived
cells arise, differentiate, and expand in mucosal-associated sites
and, after circulating systemically, travel to distant as well as
adjacent mucosal sites. These cells reside in the lamina propria
as differentiated plasma cells. Considerable evidence indicates
that distinct regulatory T-cells also develop in mucosae; these
cells are thought to influence not only the B-cell progeny of
mucosa, but also B-cell progeny in marrow and lymphoid
organs distant from mucosae. Together, these regulatory
1-cells and B-cells form a "mucosa-marrow axis" [41—43]. The
amount and class distribution of antibody produced by plasma-
cytes, be they residents of marrow or mucosae, are subject to
the regulatory influence of 1-cells. One such mechanism of
regulation, subtended by mucosal T-cell subsets, is the phe-
nomenon of "oral tolerance" [44, 45].
I will elaborate here on this notion of "oral tolerance."
Typically, exposure to antigen via a mucosal route initially
leads to sensitization to the antigen. This exposure elicits 1gM,
then lgG, and finally IgA antibodies, as well as cytotoxic and
factor-producing antigen-specific T-cells. However, protracted
antigenic exposure at a mucosal site results in elimination of
1gM and IgO antibody production, and in a loss of effector
1-cells [44—47]. Occasionally, loss of the humoral response
includes loss of IgA, but more frequently the loss is selective,
increasing IgA production, while diminishing 1gM and IgG
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synthesis. Genesis and maintenance of this state, termed "mu-
cosal tolerance" or "oral tolerance" (owing to the predom-
inance of experiments that utilize the gut as the site of antigenic
exposure), comprise an active process governed by several
regulatory T-cell subsets [48—51]. Although human data are
relatively limited, this mechanism appears to apply to humans
as well as to mice [52, 53]. Evidence that the process is active
derives from experiments in which tolerance was adoptively
transferred by T-cells and was "broken" by drugs that are toxic
for T-cells or that interfere with antigen presentation to regula-
tory T-cells [48—511. Prominent among these T-cell subsets are
"switch" cells, which promote rearrangement of immunoglob-
ulin heavy chain genes in B-cells [54, 55]. After rearrangement,
the variable portion of the molecule, with its intact binding site
for antigen, is spliced to the heavy chain constant regions
farther out along the heavy-chain gene sequence. The two
subclasses of IgA, flanking IgE, another "mucosa-associated"
class of immunoglobulin, lie at the end of the human gene
sequence. By promoting expression of "late" heavy-chain
genes, switch T-cells can select for IgA and IgE expression at
the expense of 1gM and IgG. Helper T-cells specific for IgA-
committed B-cells also have been described; again these helper
T-cells would select for IgA expression [56]. Cells that are
phenotypically and functionally suppressor cells also can aug-
ment antibody responses; such "contrasuppressor cells" also
can select for IgA by suppressing the function of IgA-specific
suppressor T-cell subsets [57—59]. T-cells selective for IgA are
enriched in mucosa-associated T cells, when compared with
spleen-associated T-cells.
In addition to these cell-based mechanisms that require
cell-to-cell contact, selection for IgA can be favored by elabo-
ration of soluble materials from T-cells. For example, popula-
tions of T-cells can promote a switch to IgA commitment and
differentiation of B-cells from remote sites by secreting IL-4
and IL-S [60—63]. Factors that bind to a particular class of
antibody are secreted by T-cells and can directly influence
B-cells as well as inducer T-cells and effector T-cells involved in
antisuppression/contrasuppression [64]. Different isotype-spe-
cific binding factors can, of course, suppress B-cell function
committed to production of different antibody classes [65—67].
Potential influence of mucosal i,nmunoregu/ation in IgA
nephritogenesis. The complicated and still-evolving area of
mucosal immunoregulation, although somewhat nebulous, of-
fers insights into the pathogenesis of IgA nephropathy. As
expected, regulation of the IgA immune response can elicit
either noxious or innocuous antibody responses. As I stated
earlier, protracted mucosal exposure to antigen normally re-
sults, via a poorly understood and concatenated mechanism, in
an immune response that almost exclusively produces IgA. In
an environment where large amounts of foreign material daily
contacts the body, IgA is teleologically an ideal defense mech-
anism. Phylogenetically, IgA probably contributed to the sur-
vival of the species [68]. It is actively transported by a specific
receptor on the epithelium lining mucosal surfaces, and thus
IgA exists in high concentration at the interface between the
body and foreign materials of the outside world [39, 40, 68]. The
potent agglutinating ability of IgA can inhibit attachment and
motility of organisms. Also, IgA can mediate antibody-depen-
dent, cell-mediated cytotoxic and phagocytic responses by
interacting with specific receptors present on phagocytes [69,
70]. Moreover, binding of IgA to macromolecules within the
mucosal lumen inhibits penetration of those macromolecules
into the lamina propria and, therefore, the body proper [71]. Yet
IgA seems to be a poor initiator, and perhaps an inhibitor of,
complement fixation [72]. This seeming defect paradoxically is
likely an advantage in the mucosal environment; were comple-
ment fixed, the epithelium might be damaged, the integrity of
the epithelial barrier might be breached, and foreign material
could penetrate freely into the host [73]. Chemotactic recruit-
ment of phagocytes to the area of complement fixation might
create a state of chronic inflammation and amplify such injury.
If mucosal tolerance fails, the aforementioned benefits of an
IgA response would be lost, and IgG synthesis rather than IgA
would be dominant. Substitution of monomeric IgG at the
expense of dimeric IgA simultaneously would result in less
agglutination, and, because IgG is not actively secreted, the
concentration of antibody in the mucosal lumen would be
lower, thus favoring entry of antigen. Such IgG antibody, and
antigen-specific cytotoxic and factor-producing T-cells, which
encounter antigen on the surface of epithelium, might produce
epithelial injury. This scenario would further favor penetration
of foreign materials. Hence, a failure of "mucosal tolerance"
can be predicted to increase the load of antigen that gains
access to the lamina propria, and ultimately to the circulation.
What of the material that does gain access to the circulation?
In the presence of a normal IgA immune response, IgA anti-
body, concentrated in the mucosal lamina propria, generates
immune complexes (IgA complexed with viral or bacterial
pathogens, or food or environmental antigens) subject to clear-
ance by the mononuclear phagocyte system. The relatively
small amount of complexes that escape such clearance are then
subject to deposition in glomeruli. The resultant deposits, with
almost exclusively nonphlogistic IgA, are unlikely to evoke
glomerular injury in the interval before they are naturally
cleared, however.
Failure of mucosal tolerance would favor a mixed-isotype
immune response, with persistent IgG and 1gM antibodies. In
addition to increased penetration of the mucosa by antigen
(expected for the reasons I just presented), the complexes that
do gain access to the mesangium would be more likely to be
noxious because of their IgG and 1gM content, which promotes
complement deposition (at least in experimental mice) [74].
Mice parenterally challenged with a specific antigen to which a
mucosal immune response has been evoked accumulate glomer-
ular deposits of IgG and/or 1gM and complement, and these
animals develop hematuria if challenged prior to the onset of
"oral tolerance." The mice develop only IgA and antigen
deposits, however, if challenged in the setting of a "pure" IgA
immune response after achievement of "oral tolerance." In
parallel experiments, in which immune complexes were pre-
pared in vitro and injected into mice, the admixture of IgG
(capable of fixing complement via the classical pathway) into
IgA-predominant complexes promoted glomerular complement
deposits and proved nephritogenic. In contrast, administration
of IgA-predominant complexes containing a structurally similar
IgG (incapable of fixing complement) did not produce hema-
turia, proteinuria, azotemia, or glomerular complement deposi-
tion [74].
The concept that admixed IgG and 1gM produce glomerular
disease appears to apply to patients as well as to experimental
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animals. Patients with IgAN who are biopsied because of overt
renal manifestations typically also have IgG and/or 1gM depos-
its. In contrast, immunohistologic study of asymptomatic pa-
tients, many from autopsies in patients with hepatobiliary
disease, often reveals mesangial IgA deposits, but without
concomitant IgG, 1gM, or C3 deposits [75—79]. Exacerbation of
IgAN is associated with acute elevations in the IgG content of
circulating immune complexes and with increased differentia-
tion of IgG-producing cells in the blood [80]. Finally, the heavy
admixture of IgG and/or 1gM, at least in some studies, is
observed in more severely affected patients, who have a greater
propensity for progression of their renal disease [81—83].
The prediction that failure of "oral tolerance" can give rise to
glomerular deposits containing IgA with IgG and/or 1gM, and
promote a greater propensity for injury, is confirmed by studies
in mice. Gesualdo et al gave two propitiously timed doses of
estradiol or cyclophosphamide to mice that had been orally
immunized continuously for 14 weeks with bovine gamma
globulin [84]. Both these drugs interfere, by different mecha-
nisms, with the genesis of "oral tolerance" [48—51]. Compared
with identically immunized mice given saline as a control, mice
given estradiol, cyclophosphamide, or both developed identical
serum antibody titers to the oral immunogen by 4 weeks; IgA
antibody in serum continued to rise and was identical in all
groups throughout the 14-week experiment. As anticipated,
"oral tolerance" began at 6 weeks, and thus the group given
saline showed a decline of IgG and 1gM antibodies. Further.
titers of these antibodies were indistinguishable from nonim-
mune age-matched control mice by 10 weeks. In contrast, the
IgG antibody titers in the serum of mice given estradiol,
cyclophosphamide, or both continued to rise until 8 weeks, and
these titers were maintained at a high level until the mice were
sacrificed at 14 weeks. As would be expected from the immune
response, in approximately 80% of the mice given estradiol,
cyclophosphamide, or both, mesangial deposits contained ap-
preciable amounts of IgG and C3, which accompanied the
predominant IgA. As with our earlier experiments [74], the
mice with a combination of lgG and C3 with IgA in the deposits
had microhematuria and mild proteinuria. Mice given saline had
comparable amounts of IgA, but lacked IgG or C3 deposits,
hematuria, or proteinuria [74, 85].
In light of this new information on mucosal immunoregula-
tion, we can envision generation of abundant immune com-
plexes containing some IgG and 1gM, but mostly IgA antibody,
via two routes. First, large amounts of antigen(s) might pene-
trate the mucosae prior to the development of "oral tolerance."
Second, the host might fail to establish isotype switching and
"oral tolerance" fully.
In the former situation, increased mucosal penetrability to
antigen, and/or an overexuberant and particularly intense,
mixed isotype humoral immune response to the antigen, would
promote rapid accumulation of abundant immune complexes
within the body proper. Enhanced mucosal penetrability per se
is not well established in patients with IgAN, although some
investigators have implicated increased uptake of various com-
mon dietary and infectious antigens in IgAN patients [7. 86].
Infection with a pathogen, however, presupposes penetration
by the organism. In mucosal infections in general, antigen
penetration does not lead to IgAN; that is, most patients
afflicted with influenza, for example, do not develop clinically
evident renal disease. However, with the same load of antigen,
more robust and rapid antibody responses might induce nephri-
tis. This situation can be produced in the experimental mouse
model [87]. Reinfection of immune mice with a parainfluenza
virus does not elicit nephritis. However, parenteral challenge
with a standard infectious dose of virus, or respiratory chal-
lenge with a hundredfold more virus than the usual infectious
dose, is nephritogenic in immune mice, if the virus is infectious
rather than inactivated [87]. These mice developed macrohe-
maturia and mild acute azotemia reminiscent of the hematuria
accompanying pharyngitis in patients with IgAN. Abnormally
low levels of antibody after an infection (low immunologic
memory) would predispose to reinfection with the same or a
serologically related strain of virus, and therefore to an abnor-
mally high mucosal penetrability by antigen, relative to normal
immune subjects. This situation is analogous to mucosal chal-
lenge with a hundredfold more virus in a normally immune host.
When coupled with abnormally accelerated antibody synthesis
after antigen challenge, lower memory antibody levels would
prove an ideal milieu in which infections could at once pene-
trate mucosae and generate a heavy immune complex load.
Increased specific IgA antibody was observed in the serum of
many IgAN patients shortly after mucosal challenge with polio
vaccine and other viral antigens in three independent series
[88—901. In addition, Waldo and Cochran demonstrated accen-
tuated decreases in in-vitro production of specific IgA antibody
later on, in the presence of increases in total IgA and specific
IgG antibody [88]. Hence, the prediction of hyperfunction both
of helper T-cells (during antigen challenge) and suppressor
T-cells (during antigen-free intervals) as an ideal milieu for IgA
nephritogenesis is documented in at least some patients with
IgAN.
It is conceivable that in the subgroup of IgAN patients with
episodic macrohematuria associated with acute "viral" infec-
tion, bouts of nephritis result from such a phasic hyperfunction
of helper and suppressor T-cells. It is well to note in this contect
that the antigen need not be, and likely is not, a single chemical
or biologic entity, but might be several distinct elements.
Serologic variants of organisms would be, at least to the extent
of the new antigenic determinants, primaryantigens. Moreover,
this proposed mechanism is not incompatible with hypotheses
that propose IgA as a rheumatoid factor or an antigen compo-
nent of immune complexes, because the IgA production insti-
gated by a viral infection could participate in complexes via
these mechanisms.
A second route to increased generation of mixed-isotype
immune complexes with predominant IgA derives directly from
the body's failure to fully establish isotype switching and "oral
tolerance." In this situation, a commensal organism or a dietary
or environmental macromolecule would evoke "mucosal toler-
ance" in normal individuals but would produce a mixed-isotype
response, with its attendant promotion of antigen penetrance
and mixed-isotype complexes, in patients with failure of "oral
tolerance." This aspect needs to be explored in patients with
IgAN, but a mixed-isotype response to persistent mucosal
antigens with failure of mucosal tolerance might account for the
subgroup of patients with microhematuria and proteinuria.
Abnormalities in IL-4 levels in IgAN patients' sera and culture
supernatants might provide the first clues in this area.
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Alterations in immunoregulation in patients ii'ith IgAN.
Further evidence of defective immunoregulation in IgAN lies in
the variety of abnormalities in lymphocyte function described in
patients with IgAN and their relatives, compared with patients
with other forms of glomerulonephritis and normal individuals.
The details are extensive and beyond the scope of this Forum:
the reader is referred to several comprehensive reviews and key
papers [5—7, 91—107]. To summarize briefly, approximately
one-half the patients with IgAN have increased serum levels of
IgA. Peripheral blood B-cells from many patients with IgAN
show abnormal spontaneous IgA secretion and, more consis-
tently, increased IgA production after mitogen stimulation.
Several investigators also reported increased fractions of pe-
ripheral blood B-cells expressing surface IgA, and production
of IgA by peripheral blood B-cells in the presence of mitogen-
activated T-cells capable of suppressing IgA synthesis by
B-cells from non-IgAN patients [93—97]. Some of these obser-
vations have not been confirmed, however [98—100]. Investiga-
tors also have described increased specific IgA antibody re-
sponses in serum to a variety of antigens 188—90]. Oral
administration of polio vaccine to IgAN patients, first-degree
relatives, and controls revealed upregulated serum IgA anti-
body in patients and relatives and, paradoxically, showed
diminished production of specific IgA in lymphocyte culture
supernatant from IgAN patients [88]. These findings suggested
IgA-specific suppression [88]. There also appears to be selec-
tive expression of some IgG subclasses in IgAN patients
relative to controls, with reciprocal differences observed in
serum and glomerular immune deposits [101, 102]: these obser-
vations suggest altered regulation of immunoglobulin isotype
expression in patients with IgAN. In addition, intriguing evi-
dence implies that genetic differences in heavy-chain switch
regions, where the variable portion of antibody heavy chains is
spliced to the constant portion of a specific antibody class, are
more frequently encountered in patients with IgAN than in
normal individuals in the general population [103, 1041.
Peripheral blood T-cells from IgAN patients. and culture
supernatants from these T-cells, are less effective at suppress-
ing IgA secretion by mitogen-stimulated B-cells than are iden-
tical preparations from normal controls [94—97, 105]. The IgA-
specific suppressor T-cell activity in IgAN patients correlated
inversely with serum IgA levels and the percentage of B-cells in
blood that express IgA on their cytoplasmic membranes [94—97,
105—107]. Patients with IgAN also manifest increased function
of T-cells, which promote IgA secretion in vitro, and increased
percentages of T-cells with surface receptors for IgA in the
circulation [94—100, 105—107]. As with the B-cell data, not all
investigators agree on all details.
Particular emphasis is needed in two areas to refine our
understanding of immunoregulation in IgAN: the difference
between regulatory status in exacerbation versus remission,
and the distinction between mucosally derived lymphocytes
versus lymphocytes derived from peripheral" lymphoid or-
gans, that is, non-mucosa-related lymphocytes. Egido and
colleagues did observe increased polymeric IgA-producing
blood lymphocytes in patients during exacerbation, an obser-
vation suggesting mucosal-specific alterations [94, 107, 108],
but several other groups have not [95—97]. Efforts at employing
the tonsil as a source of mucosal lymphocytes have yielded
findings essentially similar to those reported with peripheral
blood lymphocytes [108, 109], but because the tonsils are a
"crossroads" both for systemic and mucosal lymphocytes,
rather than a true mucosa-associated lymphoid tissue, the
results with tonsils are neither surprising nor specific for a
particular lymphoid component. Studies of lymphocyte func-
tion in IgAN patients in exacerbation versus remission are
limited, but Schena et al reported that in exacerbation of 1gAN,
peripheral blood lymphocytes in vitro differentiated to IgG- as
well as to IgA-producing cells [80]. Moreover, the lgG content
of immune-complex-like material and serum IgG levels were
elevated in exacerbation compared with remission. Such
changes were encountered more frequently in patients with
more severe cases of IgAN, but it is difficult to distinguish the
immunologic effects of azotemia from fundamental differences
in immune status that antedated renal disease.
Most recently, Gesualdo and coworkers observed differences
in interleukin (IL)-4 production by resting and mitogen-stimu-
lated peripheral blood lymphocytes and in serum IL-4 levels in
patients with IgAN compared with age- and gender-matched
normal volunteers (Gesualdo L, personal communication).
Reminiscent of the results Waldo and Cochran obtained with
specific IgA immune responses to oral polio vaccine [88], and of
some results in lymphocyte studies [94, 105, 107, 109], produc-
tion of IL-4 by peripheral blood lymphocytes from patients with
IgAN was double that by lymphocytes from normal individuals,
whereas the serum lL-4 content in the patients was only 60% of
that in controls. These responses suggest either increased
catabolism or increased receptor-mediated uptake of IL-4 in
patients with clinically evident IgAN. More extensive work
obviously is required to fully characterize the immunoregula-
tory state in specific groups of patients with IgAN. All results to
date suggest some, perhaps multiple, immunoregulatory defects
in patients with IgAN; the nature of these defects can differ
among different subpopulations of patients.
Genetic aspects of IgAN. Although agents such as cyclo-
phosphamide and estradiol can interfere with the establishment
of "mucosal tolerance" in mice [84], postnatal failure of muco-
sal tolerance is not generally recognized as a cause of defects in
mucosal immunoregulation. On the other hand, significant
evidence has been adduced that heritable factors influence the
risk of developing IgAN. Familial clustering [110—117] and
racial predilection [118] or sparing [119] are well recognized in
association with IgAN. Numerous reports have associated the
severity of, or risk for, IgAN and major histocompatibility gene
loci, notably in the DRIDQ immune-associated (La) regions [5,
6, 120] and the class-Ill genes for complement component 4
[121, 122]. Other genes or gene segments implicated are the
switch regions of immunoglobulin heavy-chain genes [103, 104]
and the genes for complement component 3 [121, 122]. This
abundance of data is tantalizing but difficult to evaluate as yet;
at present, the only confirmed and uncontested data apply to
the complement phenotypes, as reviewed elsewhere 1123].
Nonetheless, genetic studies support an immunoregulatory
defect in at least some patients with IgAN. Such genetic
influence might underlie abnormal lymphocyte function in pa-
tients with IgAN as well as their first-degree relatives, as I
already noted [5—7, 88—100, 105—109, 124].
The mechanism of injury in IgAN. The mesangium contrib-
utes appreciably to glomerular pathophysiology [125], including
the genesis of proteinuria [126]. Immune complexes, the mem-
1222 Nephro!ogy Forum: Immunoregulat ion and IgA nephropaihy
brane attack complex of complement, and cytokines from
inflammatory cells promote functional and morphologic
changes in the mesangium; these changes include calcium
mobilization and mesangial contraction. They also include the
release of multiple substances including vasoactive prostaglan-
dins, platelet activating factor, proteolytic enzymes, reactive
oxygen intermediates, and cytokines such as interleukin-1 and
tumor necrosis factor [127—140]. Mesangial cells also can pro-
liferate upon insertion of membrane attack complex into cell
membranes [133]. Mesangial cells synthesize platelet-derived
growth factor, an autocrine mitogen [141, 142], and this synthe-
sis can be augmented after stimuli such as growth factors,
eicosanoids and cytokines, in turn stimulated by immune com-
plexes and complement. The precise interplay among these
mechanisms and metabolites remains unclear, and we are only
beginning to understand the influence of IgA on their modula-
tion. My own belief is that the basic principles of mesangial
structure, function, and interaction with immune reactants
underlie glomerular function in IgAN and other forms of
glomerulonephritis equally.
IgA deposition as an epiphenomenon. Save for macrohema-
tuna, the factors governing long-term prognosis in IgAN are
very similar to those in membranous nephropathy [143], and
possibly are generic for glomerular disease in general. Also,
histologically and clinically matched cases of mesangial prolif-
erative glomerulonephritis, with and without dominant IgA,
have similar long-term courses in Japan and New Mexico [144,
145]. A minority of patients with IgAN (25%) have IgA as the
only immunoglobulin deposited, whereas many asymptomatic
patients with liver disease have abundant mesangial IgA depos-
its but have no overt renal disease [75—79]. As noted before, in
experimental mice with IgAN induced by oral immunization or
injection of immune complexes, concurrent deposits of IgG and
1gM are important elements, apparently because they promote
glomerular C3 deposits, which are potent at nephntogenesis
[74]. In another experimental system induced by injection of
immune complexes, IgG/IgM deposits are unimportant, but the
antigen structure is critical for nephritogenesis [146]. These
observations collectively suggest that IgA per se is neither
noxious to the glomerulus nor intrinsically pathophysiologically
important.
An alternative view holds that the IgA component of glomer-
ular immune deposits in IgAN is a functionally important
ingredient in immune deposition or pathogenesis. Introduction
of IgA into an immune lattice, even as small percentages of the
total immunoglobulin, profoundly affects the complement-acti-
vating potential of that lattice; it appears that IgA somehow
inhibits IgG- and/or 1gM-mediated complement fixation [72].
Therefore, IgA-rich immune complexes likely have a comple-
ment:immunoglobulin ratio quite distinct from similar com-
plexes lacking IgA. This ratio could significantly influence the
propensity of immune complexes for depositing in the kidneys.
In primates, IgA immune complexes are cleared from the
circulation more slowly than are similar IgG immune complexes
with the same molecular weight and charge, presumably be-
cause of the less efficient operation of the erythrocyte comple-
ment receptor (CR1) clearance mechanism on the relatively
C3b-poor IgA complexes [147]. Hence, IgA immune complexes
are deposited more widely than are similar LgG immune com-
plexes; glomerular deposits of IgA immune complexes are
threefold that of IgG immune complexes. The existence of
defects in clearance of IgA immune complexes in patients with
IgAN versus normal volunteers remains controversial [148,
149]. Even in the absence of defective clearance, however, a
predilection for IgA incorporation into immune complexes
would favor glomerular deposition of immune complexes rela-
tive to patients with less propensity for IgA synthesis; forma-
tion of complexes with the same total amount of specific
antibody, but a higher percentage of IgA, would favor less
complement fixation, impaired clearance, and more generalized
immune deposition.
Another means by which IgA might play a pathogenetic role
is by virtue of its binding to fibronectin (Woodroffe A, Schlon-
dorif D, independent personal communications) [150]. Fi-
bronectin is an abundant constituent of the extracellular matrix
of the glomerular mesangium. According to one hypothesis,
IgA immune complexes or perhaps IgA alone would preferen-
tially accumulate in the mesangium by virtue of the binding of
IgA to the fibronectin component of the glomerulus. If IgG
and/or 1gM and C3 were associated with these immune com-
plexes, they likewise would deposit and initiate nephritis. Some
investigators have posited that IgA immune complexes might
deposit first, followed by accumulation of IgO and/or 1gM with
specificity either for an antigen component, or for the IgA,
within the IgA immune complexes. In either event, the affinity
of IgA for fibronectin could serve as a means of "targeting"
immune complexes to the mesangium. In addition, IgA immune
complexes could influence mesangial cell metabolism by inter-
fering with cellular interactions with fibronectin. Other, analo-
gous interactions of IgA and IgA immune complexes with the
glomerulus are possible.
Finally, the relationship between IgA and IgG and comple-
ment components of glomerular deposits might not be at the
level of initiation of injury but rather at the level of amplification
of injury. Hernando et al recently reported that immune com-
plexes prepared in vitro with only IgA antibody and similar
immune complexes prepared with only IgG both elicited super-
oxide anion and tumor necrosis factor release from mesangial
cells in culture [140]. Although both isotypes elicited compara-
ble responses, the addition of fresh serum as a source of
complement augmented the response to (complement-fixing)
IgG-containing immune complexes, but the fresh serum did not
influence the response to IgA immune complexes [140]. If these
in-vitro data can be extrapolated to in-vivo conditions, they
provide several explanations. First, adding sufficient IgG (or
perhaps 1gM) to a predominantly IgA immune lattice would
favor some complement fixation, albeit much less than would
obtain were all the antibody of the IgG or 1gM class, Comple-
ment fixation then could augment mesangial cell responses,
presumably including contraction, and production of ei-
cosanoids, IL-I, superoxide, and tumor necrosis factor. On the
other hand, if the antigen itself could promote complement
fixation, concurrent IgG or 1gM deposits would be unnecessary
for the synergistic effects of complement. Moreover, if the
antigen structure resulted in a high density of IgA antibody, the
local concentration of IgA alone might be high enough to elicit
maximal mesangial cell responses, and augmentation by com-
plement would be unnecessary.
Conclusion. The subject of IgAN is complicated and provoc-
ative. Glomeruli likely respond to IgA deposits as they do to
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any immune stimulus, perhaps with minor variations. The IgA
itself, while apparently not directly noxious, seems to consti-
tute a physiologically important element and to be a marker
associating mucosal antigenic exposure with disease. Specifi-
cally, IgA may impair complement-mediated clearance of im-
mune complexes from the circulation and/or promote mesangial
deposition of complexes by binding to endogenous glomerular
components, such as fibronectin, perhaps on a lectin-like basis.
I believe that the primary defect in IgAN lies within the
regulation of the immune response. Either of two defects might
exist. Overly wide swings in antibody production, due to
hyperfunction both of suppressor T-cells (during antigen-free
intervals) and helper T-cells (during periods of antigen expo-
sure, which incite disease exacerbations), appear to be one
defect. The other potential defect is inadequate suppression of
"systemic" IgG and/or 1gM antibody responses to persistent
mucosal exposure to environmental or dietary antigens. These
specific defects likely give rise, respectively, to the major
syndromes of IgAN: episodic macrohematuria and persistent
proteinuria and hematuria. I hope that tangible, convincing data
soon will emerge from the circumstantial evidence now framing
the perspective of IgAN as a primary disorder of the immune
system. Recognition of specific immune defects might also
permit noninvasive specific diagnosis of IgAN and perhaps will
allow specific therapy in the future.
Questions and answers
DR. JOHN T. FIARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): If your hypothe-
sis is correct, that IgA deposition depends on altered produc-
tion of IgA and IgG, which in turn depend on IL-4 function, one
would speculate that IL-4 production would be stimulated when
IgA nephropathy flared and that cellular IL-4 production would
be normal when patients were in remission. Have such studies
been performed?
DR. EMANCIPATOR: The distinction between active disease
and disease in remission, particularly in the episodic macrohe-
maturia group, is absolutely critical. Part of the reason that
we've had trouble in understanding the lymphocyte function
data is because we haven't made the distinction between
patients in remission versus those in exacerbation. Nor have we
made the distinction between patients with episodic macrohe-
maturia versus those with persistent proteinuria and microhe-
maturia. In answer to your question, the patients with active
episodic macrohematuria produced 300 to 400 pg/mI IL-4,
whereas patients in remission synthesized 35.3 4.8 pg/mI. In
contrast, normal volunteers and patients with glomerulonephri-
tis without IgA immune deposits produced only 12.9 3.9 and
11.3 4.5 pg/mI, respectively. I think these are critical controls
regarding the IL-4 data.
DR. HARRINGTON: Do you have control data of another sort,
that is, data from active patients with Henoch-Schonlein pur-
pura?
DR. EMANCIPATOR: I think that Henoch-SchOnlein purpura
nephritis should also be stratified according to active versus
remission stages. I suspect that lymphocyte function studies
will reveal results similar to IgAN with episodic macrohema-
tuna.
DR. JAMES STROM (Chief, Division of Nephrology, St. Eliz-
abeth's Hospital, Brighton, Massachusetts): If I understood
you correctly, you postulated a defect in mucosal IgA process-
ing in these patients, which leads to overstimulation of IgG,
which in turn causes nephritis in the presence of complement.
Why, then, do these patients demonstrate prominent IgA dep-
osition?
DR. EMANCIPATOR: I didn't mean to imply that I believe
there is a defect in IgA processing in the gut of patients with IgA
nephropathy. I am not aware of any evidence, nor do! have the
bias, that there's a defect in IgA processing in these patients
versus normal people. In fact, many patients with IgA nephrop-
athy have overabundant IgA production, and I'm not aware of
any difference in secretory IgA levels in that population.
Presumably if serum IgA is increased, then IgA secretion is
increased as well. The problem, persistence of IgG production,
reflects a defect not in IgA processing but rather in T-cells
turning off IgG production. On the other hand, your question
does bring up the possibility that if in fact there were a defect in
secretory component-mediated transport of IgA or in local
immunity, a patient would have serum IgA but not mucosal
IgA. Some individuals do have such a condition. These people
would have a higher risk of mucosal infection, but normal
serum antibody, potentially rich in IgA, capable of generating
immune complexes with the antigen, which enters the body
consequent to deficient local immunity. The immune complexes
in turn could localize within the kidney.
DR. MICHAEL MADAIO (Division of Nephrology, New En-
gland Medical Center, Boston, Massachusetts): I know you've
spent the last hour discussing this, but could you summarize
your working hypothesis for the mechanism of immune deposit
formation in IgA nephropathy?
DR. EMANCIPATOR: My working hypothesis is that the anti-
gen penetrates and combines with the antibody in the lamina
propria of the airway or intestine, gains acccess to the circula-
tion, and deposits as such. Perhaps some immune complexes
also form within the mucosal lumen and are transported, but it's
fairly well established that immune complexes are less likely
than the free antigen to penetrate through the mucosal barrier.
The idea of in-situ formation, although not emphasized in the
context of mesangial deposits, merits further consideration.
In-situ mechanisms traditionally have been emphasized in as-
sociation with epimembranous deposits, largely because it is
difficult to elicit such deposits by injecting pre-formed immune
complexes, whereas mesangial and subendothelial deposits are
readily formed. Mesangial deposits may form via in-situ mech-
anisms principally, or in concert with deposition of circulating
immune complexes. I already mentioned fibronectin-IgA bind-
ing. Antigens could bind to mesangium, and then IgA in turn
could bind to antigen. In fact, Amore has demonstrated just
such a mechanism with gliadin as antigen [1511.
DR. MADAIO: Even during periods of clinical remission,
patients with IgA nephropathy typically have glomerular depos-
its of IgA. What factors precipitate clinical episodes of nephri-
tis? Is it purely a quantitative phenomenon? Or is it related to a
qualitative factor such as either deposition of complement-
fixing antibodies or an isotype switch to IgG?
DR. EMANCIPATOR: I believe the factor is largely qualitative.
In some cases, the IgA persists without clinically evident
nephritis. A few reports suggest that the IgG and C3 are less
abundant during remission [3, 18, 29, 31, 83], but this evidence
is scanty at best. Patients with cirrhosis of the liver or hepato-
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biliary disease have been used as a model; they have abundant
IgA deposits, yet the vast majority of these patients have no
clinical manifestations of renal disease. We had speculated in
Clinical Nephrology a couple of years ago that it's the IgG
production that distinguishes exacerbation from remission [5].
My belief has now been substantiated in IgAN patients by
Schena [80].
DR. HARRINGTON: You mentioned that patients with the
episodic gross hematuria mode of presentation of IgAN, par-
ticularly, develop macrohematuria within hours of a clinical
viral illness such as pharyngitis. You have proposed that
subsequent to viral infection, antibody specific for viral anti-
gens is produced and combines with the antigens, generating
immune complexes that deposit in the kidney. Can one produce
enough antibody within the first few hours of a viral pharyngitis
to account for all the changes in exacerbation?
DR. EMANCIPATOR: The rate of the immune response de-
pends on whether the responding antigen-committed cells are
lymphocytes, plasma blasts, or plasmacytes, and where in the
body these cells reside relative to antigen entry. Viral infec-
tions, and less so bacterial infections, often are not clinically
manifest until after the agents have infected the host, repli-
cated, and shed antigens. This is true for all viruses, but
particularly those that kill the cell in which they replicate. The
virus is safely tucked away, replicating. At the same time,
during the incubation period, the immune system is also re-
sponding, because it was exposed to the antigen at the same
time the infected mucosa was. When a host infection produces
clinical manifestations, the immune system already has been in
action for 4 to 5 days, plenty of time for a secondary immune
response to produce multi-milligram quantities of antibody,
which can rapidly deposit and incite overt nephritis.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): The use of prednisone to treat
IgA nephropathy complicated by the nephrotic syndrome has
met with variable success. Your data in mice that were given
cyclophosphamide and in which the IgG level remained ele-
vated suggest that this type of therapy could make the disease
even worse. What can you say about immune modulators in the
treatment of IgA nephropathy?
DR. EMANCIPATOR: Woo's group in Singapore [37], and
Kobayashi's group in Sasamihara, Japan [152], have had suc-
cess in proteinuric patients at high risk of developing end-stage
renal disease and in patients who present with nephrotic-range
proteinuria by treating them with prednisone, as though they
had idiopathic nephrotic syndrome. Controversy exists regard-
ing the relationship between IgA nephropathy and nephrosis:
are these two processes, or is nephrosis a manifestation of
IgAN? In nephrotic patients with IgA nephropathy, it seems
that prednisone therapy not only reduces the proteinuria, but
also increases the likelihood that patients will maintain good
renal function for a longer period.
Regarding our mice given cyclophosphamide, we gave two
doses, each 100 mg/kg as a single shot, and compared these
mice with animals given saline injections [84]. The effects we
elicited in the mice probably differ fundamentally from the
effects induced with treatment of nephrotic syndrome, in which
cyclophosphamide is administered at a dose of 1—2 mg/kg/day
for as long as 6 months. I cannot predict the effect of sustained
therapy with cyclophosphamide (1—2 mg/kg/day) on immune
function in IgAN, but I agree that this approach is worth trying.
Because I consider IgAN an immunologic disease, I believe that
some form of immunotherapy ultimately will prove useful.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): As you know, IgA nephropathy
frequently recurs in allografts, especially in grafts from living
related donors, although the graft is rarely lost. Have any
comparative lymphocyte studies been carried out during the
pre-uremic clinical stage and also after renal transplantation?
DR. EMANCIPATOR: No, and your question prompts two
other points. First, the immunologic milieu of patients with IgA
nephropathy appears to be different from that in normal indi-
viduals. Save for the effects of immunosuppressive agents, that
milieu shouldn't change in the presence of a renal transplant.
Why, then, shouldn't IgAN recur in transplants? Second, how
do dialysis and the elimination of transient or chronic uremia
influence the immune dysregulation in. patients with IgAN?
Lymphocyte studies in patients with IgA nephropathy generally
were done on patients with normal serum creatinine levels
[88—97]. It would be interesting to measure lymphocyte function
in the patient with an allograft. It's a very complicated system
comprising the allograft itself, the immune response to the
allograft, and the immunosuppressive therapy. Such studies
might prove critically important. Finally, kidneys from donors
with silent IgAN have been transplanted into non-IgAN hosts
[153—155). The IgAN deposits resolve, an occurrence I find
fascinating. This reversal might be unexpected, but I believe
that immune deposits in the glomeruli are reversible.
DR. MADIAS: Only 40% to 50% of patients with IgA nephrop-
athy have elevated circulating levels of IgA. What differentiates
these patients from the rest?
DR. EMANCIPATOR: We are in the process of looking at this
issue as it relates to IL-4 or IL-S levels. Usually subjects for
lymphocyte studies have been consolidated into one group, We
are stratifying patients according to disease activity and accord-
ing to serum IgA levels. I am not aware of any lymphocyte
function study in which patients with high levels of IgA were
distinguished from those with normal serum levels of IgA, so I
cannot answer your question.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): What have we learned from the genetic
studies of families with IgA nephropathy?
DR. EMANCIPATOR: As I mentioned, many family studies
suggest that some of the same defects observed in IgA nephrop-
athy also occur in first-degree relatives. Several groups, most
notably Julian and Wyatt, alone and in collaboration with
Egido, have shown clear familial risk for IgAN [94, 107, 116,
117, 121, 123]. Schena and Sakai also have suggested a genetic
basis for lymphocyte function abnormalities [92, 93, 156]. Julian
and colleagues found changes in the nucleic acid sequences
(assessed by restriction fragment length polymorphisms) in the
IgG2, IgG4, and an IgG pseudogene located between the IgAl
and IgA2 genes [104]. Demaine and colleagues report increases
in the frequency of homozygotes with either allele coding for
the 1gM switch regions in patients with IgAN [103]. Patients
with a heterozygous switch region have less likelihood of
developing IgA nephropathy; the relative risk is about 2.0- to
2.5-fold. Finally, Wyatt's studies clearly show that both C3 and
C4 complement phenotypes, particularly C4 null alleles, are
strongly related to risk for and severity of IgAN, but the
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mechanism linking complement phenotypes to disease is ob-
scure [122, 123].
DR. KURTIN: After a similar illness, Henoch-Schonlein pur-
pura can develop in one child and isolated IgA nephropathy in
a sibling. Could you speculate on what might cause one child to
have a systemic manifestation of the disease and the other child
to have localized disease? Also, why do the vast majority of
children with Henoch-SchOnlein purpura experience complete
resolution of their disease?
DR. EMANCIPATOR: Let me answer the second question first.
A lot of patients with Henoch-SchOnlein purpura develop the
disease because they have an immature immune system. If you
believe the working hypothesis that I presented to you, then
you have to agree that young people are at higher risk than older
people for having an overly enthusiastic immune system. The
difference that I see between Henoch-Schönlein purpura and
IgA nephropathy is a difference of degree. That is, with more
immune complexes, systemic disease is more likely. However,
as the immune system matures, proper immunoregulation su-
pervenes. I believe that in Henoch-Schönlein purpura nephritis,
the disease resolves as the immune system learns to regulate
itself.
Regarding your first question, an intriguing hypothesis is
emerging from the data that Montinaro and Rifai have gathered
from a bacterial polysaccharide-induced model of IgA nephrop-
athy. In that model, gut lesions and purpura, or purpura and
glomerular lesions as well as macrohematuria develop (personal
communication). The location and severity of the lesions de-
pend on the amount of antigen, relative amount of antibody,
and strain of mice. The nature of the antigen dramatically
influences the clinical expression of the disease, because dif-
ferent pneumococcal strains' polysaccharides behave differ-
ently. Perhaps Henoch-Schönlein purpura is an expression of
an antigen-dependent process.
DR. MADIAS: Do we have any insights into the geographic
distribution of IgA nephropathy?
DR. EMANCIPATOR: The incidence of IgAN differs dramati-
cally in different countries. When expressed as a percentage of
all renal biopsies, the incidence of IgAN ranges from 5% in the
United States and the United Kingdom to nearly 50% in
Singapore and Japan [1—7]. Although genetic and environmental
factors undoubtedly influence this incidence, active urine
screening and aggressive biopsy policies are important factors
as well. In the nations with higher rates of diagnosis of IgAN,
more IgAN patients have mild urinary abnormalities, and
physicians display a higher propensity to perform renal biopsy
and/or to order routine urinalysis in patients who have mild
urinary abnormalities. The converse is true in countries with a
low rate of renal biopsy. In countries with an apparently low
incidence of IgAN, there is an inverse correlation between
macrohematuria and/or proteinuria in excess of I g/day,
whereas this correlation does not exist in countries where IgAN
is frequently diagnosed [7].
DR. MADIAS: Would you speculate on the mechanisms re-
sponsible for progression of IgA nephropathy?
DR. EMANCIPATOR: We're going to need a lot more time to
discover the mechanisms. Patients with episodic macrohema-
tuna have a lot of activity in their glomeruli for a short amount
of time; then they seem to return to a normal state. Patients
with persistent microhematuria and/or proteinuria progress
slowly but consistently over a long period. Proteinuria itself
might lead to progression of the nephropathy, according to
Brenner's hyperfiltration model [157]. I have an alternate view.
I have a rat model that I have not presented here. This rat model
is basically the mouse model that I described earlier at 6 weeks.
In that system, the animals develop mixed IgG. IgA, and C3
immune deposits in the kidney, and they develop microhema-
tuna and significant proteinuria. The proteinuria is heavy for a
rat, about 20—25 mg/hour; this level is abnormal, but not near
nephrotic range. We measured glomerular eicosanoid produc-
tion, and we have carried out hemodynamic measurements on
whole kidneys in these rats. We are collaborating with Badr on
micropuncture studies. I am aware of no other model of
immunologic disease in which vasoconstrictor thromboxane is
increased without anti-vasoconstrictor prostaglandins being in-
creased to a parallel if not a greater degree. Indeed, in most
other models, prostaglandin E2 levels were much higher when
compared to control values than were the thromboxane levels
[158, 159]. In our rat model, thromboxane is synthesized in
diseased glomeruli at about 2 times its basal level. At the same
time, we have seen a very slight increase in prostaglandin E,, a
rise that is not statistically significant. As one might predict, the
hemodynamics are compatible with efferent arteriolar constric-
tion, namely, renal plasma flow decreases and filtration fraction
is constant. On the other hand, a thromboxane receptor antag-
onist plus thromboxane synthetase inhibitor can restore the
renal plasma flow to basically normal levels, but under these
conditions, filtration fraction is decreased at the whole-kidney
level.
These observations suggest that mesangial contraction is
present in this model of IgAN. In unmanipulated rats with
IgAN, this contraction is offset, in terms of filtration fraction,
by thromboxane-induced efferent arteriole constriction. Be-
cause contraction leads to matrix synthesis, hyperplasia, and
hypertrophy in smooth muscle, it also might lead to these
changes in contractile mesangial cells. Matrix synthesis would,
in turn, generate sclerosis. In addition, the rich thromboxane
synthesis in this model might contribute to sclerosis. Klotman
has shown that thromboxane analogues stimulate matrix syn-
thesis by mesangial cells in culture [160]. These two factors,
alone or in concert, might underlie progression to glomerulo-
sclerosis.
Reprint requests to Dr. S. Emancipator, Institute of Pathology, 2085
Adelbert Road, Cleveland, Ohio 44106, USA
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